drugset / Trial / NCT04562597

A Pilot Trial to Determine the Effective N-acetylcysteine Dose for Opioid Reduction for Spine Surgery.

NCT04562597

Phase 1/2 Completed 50 enrolled Medical University of South Carolina
RandomizedSequentialTriple-blindTreatment

Summary

Determine the optimal dose of IV N-acetylcysteine (NAC) to produce opioid reduction following spine surgery and estimate the difference in opioid consumption between placebo and the selected optimal dose.

Timeline

Start
2021-01-20
Primary completion
2022-05-20
Completion
2022-05-21

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator N-acetylcysteine Small molecule 50 mg/kg Intravenous
Comparator N-acetylcysteine Small molecule 100 mg/kg Intravenous
Comparator N-acetylcysteine Small molecule 150 mg/kg Intravenous

Indications

No indication recorded.